Notably, an ongoing neoadjuvant Phase 2 study including patients with PCa is comparing the effects of ADT with or without chemotherapeutic agents against SRC or MEK (degarelix, enzalutamide, trametinib, or dasatinib), by evaluating the inhibition of mesenchymal markers N-cadherin and vimentin (NCT01990196). The gene discussed is SRC; the disease is posterior cortical atrophy.